137 related articles for article (PubMed ID: 31734798)
1. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial.
Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
3. Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study.
Kekäle M; Söderlund T; Koskenvesa P; Talvensaari K; Airaksinen M
J Adv Nurs; 2016 Sep; 72(9):2196-206. PubMed ID: 27113362
[TBL] [Abstract][Full Text] [Related]
4. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
de Almeida MH; Pagnano KB; Vigorito AC; Lorand-Metze I; de Souza CA
Acta Haematol; 2013; 130(1):16-22. PubMed ID: 23363706
[TBL] [Abstract][Full Text] [Related]
5. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
Jiang Q; Yu L; Gale RP
J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
[TBL] [Abstract][Full Text] [Related]
6. Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital.
Lee PM; Chang CT; Yusoff ZM
Int J Clin Pharm; 2021 Feb; 43(1):46-54. PubMed ID: 32524510
[TBL] [Abstract][Full Text] [Related]
7. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
8. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS
Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021
[TBL] [Abstract][Full Text] [Related]
9. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Cole AL; Jazowski SA; Dusetzina SB
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
[TBL] [Abstract][Full Text] [Related]
10. Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia.
Hosoya K; Mochinaga S; Emoto A; Yokoo H; Tokushima H; Egoshi M; Sueoka-Aragane N; Kimura S
Int J Clin Oncol; 2015 Dec; 20(6):1203-10. PubMed ID: 26002407
[TBL] [Abstract][Full Text] [Related]
11. Two-Way Clinical Messaging in a CML Specialty Pharmacy Service Model.
Sawicki C; Friend KE; Patel R; Polinski JM; Singh S
J Manag Care Spec Pharm; 2019 Nov; 25(11):1290-1296. PubMed ID: 31663460
[TBL] [Abstract][Full Text] [Related]
12. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
13. Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors.
Rychter A; Jerzmanowski P; Hołub A; Specht-Szwoch Z; Kalinowska V; Tęgowska U; Seferyńska I; Kołkowska-Leśniak A; Lech-Marańda E; Góra-Tybor J
Med Oncol; 2017 Jun; 34(6):104. PubMed ID: 28444623
[TBL] [Abstract][Full Text] [Related]
14. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.
Haque R; Shi J; Chung J; Xu X; Avila C; Campbell C; Ahmed SA; Chen L; Schottinger JE
J Am Pharm Assoc (2003); 2017; 57(3):303-310.e2. PubMed ID: 28259737
[TBL] [Abstract][Full Text] [Related]
15. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
Jiang Q; Wang H; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2619-2630. PubMed ID: 28894944
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
[TBL] [Abstract][Full Text] [Related]
17. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.
Schoenbeck KL; Flynn KE
Curr Hematol Malig Rep; 2021 Dec; 16(6):491-499. PubMed ID: 34648119
[TBL] [Abstract][Full Text] [Related]
18. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
19. Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.
Kim Y; Go TH; Jang J; Lee JB; Lim ST; Shim KY; Lee JI; Kong JH
Korean J Intern Med; 2021 Nov; 36(6):1450-1458. PubMed ID: 34742178
[TBL] [Abstract][Full Text] [Related]
20. Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre-Post Intervention Multicenter Pilot Study.
Leader A; Benyamini N; Gafter-Gvili A; Dreyer J; Calvarysky B; Amitai A; Yarchovsky-Dolberg O; Sharf G; Tousset E; Caspi O; Ellis M; Levi I; De Geest S; Raanani P
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e449-e461. PubMed ID: 30030034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
